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Abstract 
We report results of molecular dynamic (MD) simulations on N-terminus mutants of the 
copper-bound, amyloid-β ;Aβ) peptide. Eight stƌuĐtuƌes of Aβ ǁeƌe ŵodelled, iŶĐluding 
seven mutant peptides in addition to the unaltered wild-type (WT). Trajectories analysed for 
eaĐh iŶdiǀidual sǇsteŵ ǁeƌe all appƌoǆiŵatelǇ ϭ.ϰ μs iŶ leŶgth, ǇieldiŶg a total of oǀeƌ ϭϭ μs 
in total. The impact of these mutations are marked and varied compared to the wild-type 
peptide, including effects on secondary structure, stability and conformational changes. 
Each system showed differing levels of stability with some showing consistent, compact 
conformations whereas others displayed more flexible structures. Contrasts between 
comparable mutations at similar sites, such as A2T/A2V and D7H/D7N, show the location as 
well as the type of mutation have effects on protein structure observed in Ramachandran 
plots. We also report notable changes in peptide structure at residues remote to the site of 
suďstitutioŶ shoǁiŶg these ŵutatioŶs iŶflueŶĐe the eŶtiƌetǇ of Aβ. Salt-bridge profiles show 
this most clearly: addition or removal of charged residues affecting all salt-bridge 
interactions present in WT, even those remote from the site of mutation. Effects on 
secondary structure differ between mutations, most notably a change in incidence of β-
strand, which has been linked to enhanced aggregational properties for the peptide. GFN2-
xTB semi-empirical calculations show clear differences in binding energies of the copper-
centre for each system.  
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Introduction 
Alzheiŵeƌ’s disease ;ADͿ is a pƌogƌessiǀe ŶeuƌodegeŶeƌatiǀe disease aĐĐouŶtiŶg foƌ tǁo-
thiƌds of all deŵeŶtia diagŶosesϭ,Ϯ. PƌojeĐtioŶs estiŵate the total Ŷuŵďeƌ of people affliĐted 
ǁith this ĐoŶditioŶ gloďallǇ ǁill ďe appƌoǆiŵatelǇ ϰϮ ŵillioŶ iŶ ϮϬϮϬϯ ĐausiŶg gƌeat stƌaiŶ oŶ 
patieŶts, faŵilies aŶd the healthĐaƌe sǇsteŵ. ChaƌaĐteƌistiĐ ŶeuƌofiďƌillaƌǇ taŶgles aŶd 
plaƋues Đoŵpƌised of iŶsoluďle aŵǇloid-β ;AβͿ aƌe keǇ to AD diagŶosisϰ,ϱ, aloŶg ǁith 
iŶĐƌeased leǀels of tƌaŶsitioŶ ŵetalsϲ,ϳ. These deposits aƌe a hallŵaƌk of AD pathologǇ, iŶ 
additioŶ to leǀels of soluďle Aβ oligoŵeƌiĐ pƌeĐuƌsoƌ speĐies ǁhiĐh haǀe ďeeŶ assoĐiated 
ǁith ŶeuƌotoǆiĐitǇϴ,ϵ.  
Cases of deŵeŶtia aƌe ĐoŵŵoŶlǇ iŶfeƌƌed to ďe a staŶdaƌd oĐĐuƌƌeŶĐe as paƌt of the ageiŶg 
pƌoĐess. Yet sǇŵptoŵs aŶd diagŶosis haǀe also ďeeŶ oďseƌǀed iŶ ǇouŶgeƌ iŶdiǀiduals ;< ϲϱ 
Ǉeaƌs oldϭϬͿ due to geŶetiĐ alteƌatioŶs iŶ the aŵiŶo aĐid seƋueŶĐe of Aβϭϭ. These iŶstaŶĐes of 
AD aƌe ƌefeƌƌed to as eaƌlǇ-oŶset faŵilial Alzheiŵeƌ's disease ;EOFADͿ, aŶd aĐĐouŶt foƌ ϱ% of 
AD diagŶosesϭϮ. We foĐused oŶ ϳ kŶoǁŶ ŵutatioŶs ǁithiŶ the N-teƌŵiŶus of Aβϭϯ,ϭϰ ;Figuƌe 
ϭͿ. “oŵe ŵutaŶts Đause aŶ iŶĐƌease iŶ pƌoduĐtioŶ of the peptide fƌoŵ its pƌeĐuƌsoƌ pƌoteiŶϭϱ 
;APPͿ suĐh as EϭϭKϭϲ. IŶĐƌeased pathogeŶiĐitǇ has also ďeeŶ oďseƌǀed iŶ AϮVϭϳ aŶd KϭϲNϭϴ 
Đaƌƌieƌs ǀia ƌeĐessiǀe aŶd doŵiŶaŶt-heteƌozǇgous geŶotǇpes ƌespeĐtiǀelǇ. CoŶǀeƌselǇ, 
pƌoteĐtiǀe ǀaƌiaŶts shoǁ aŶ oǀeƌall deĐƌease iŶ aŵǇloidogeŶesis, suĐh as iŶ the Đase of 
AϮTϭϵ. UŶŵutated, ǁild-tǇpe Aβ is heƌeďǇ ƌefeƌƌed to as WT. 
 
Figure 1 AŵiŶo aĐid seƋueŶĐe foƌ N-teƌŵiŶal of WT, highlightiŶg ϳ kŶoǁŶ ŵutatioŶs; 
ƌesidues assoĐiated ǁith ĐooƌdiŶatioŶ of Cu;IIͿ aƌe highlighted ǁith aŶ asteƌisk. 
 
NatuƌallǇ oĐĐuƌƌiŶg ioŶs suĐh as )Ŷ;IIͿ, Fe;IIͿ aŶd Cu;IIͿ haǀe a pƌoĐliǀitǇ to ďiŶd to a ƌaŶge of 
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ďiologiĐal ligaŶds, gƌaŶtiŶg theŵ high affiŶitǇ foƌ AβϮϬ, paƌtiĐulaƌlǇ thƌough ŶuĐleophiliĐ 
ƌesidues suĐh as His ;at positioŶs ϲ, ϭϯ aŶd ϭϰͿ aŶd Asp ;positioŶ ϭͿϮϭ. Cu;IIͿ ďiŶds to Aβ ǀia a 
distoƌted sƋuaƌe-plaŶaƌ Đoŵpleǆ at the N-teƌŵiŶal ϭ-ϭϲ ƌesidues of AβϮϮ. CooƌdiŶatioŶ of 
Đoppeƌ ĐaŶ lead to geŶeƌatioŶ of ƌeaĐtiǀe oǆidatiǀe speĐies ;RO“Ϳ ǁhiĐh iŶ tuƌŶ eŶĐouƌage 
foƌŵatioŶ of iŶteƌŵoleĐulaƌ ĐƌossliŶks ďetǁeeŶ ŵetallo-pƌoteiŶsϮϯ,Ϯϰ. These ŵetal-peptide 
Đoŵpleǆes, aĐĐoŵpaŶied ďǇ a disƌuptioŶ iŶ pƌoduĐtioŶ aŶd ĐleaƌaŶĐe of AβϮϱ,Ϯϲ, lead to 
eŶhaŶĐed aggƌegatioŶ aŶd suďseƋueŶt foƌŵatioŶ of Đeƌeďƌal ŶeuƌotoǆiĐ speĐiesϮϳ,Ϯϴ. CeƌtaiŶ 
ŵutatioŶs ĐaŶ pƌoǀide alteƌŶatiǀe ŵodes of ďoŶdiŶg to ŵetals suĐh as Đoppeƌ oƌ ziŶĐ; 
ƌeplaĐeŵeŶt of ŵetal-ďiŶdiŶg histidiŶe iŶ HϲRϮϵ, oƌ the additioŶ of aŶotheƌ histidiŶe iŶ the 
DϳH ǀaƌiaŶtϯϬ aƌe paƌtiĐulaƌlǇ Ŷotaďle iŶ this ĐoŶteǆt. These ŵutaŶts, as ǁell as DϳNϯϭ 
suďstitutioŶ, aƌe fouŶd to affeĐt seĐoŶdaƌǇ stƌuĐtuƌe aŶd ƌates of foƌŵatioŶ of ŶeuƌotoǆiĐ 
stƌuĐtuƌes of AβϯϮ. 
AŶ iŶĐƌease iŶ β-ĐhaƌaĐteƌ iŶ the seĐoŶdaƌǇ stƌuĐtuƌe of the Aβ peptide has ďeeŶ liŶked ǁith 
aŶ eŶhaŶĐed pƌoĐliǀitǇ foƌ aggƌegatioŶϯϯ. MoleĐulaƌ dǇŶaŵiĐs ;MDͿ seeŵs a suitaďle ĐhoiĐe 
foƌ iŶǀestigatiŶg the iŶteƌaĐtioŶs aŶd stƌuĐtuƌes of this pƌoteiŶ ǁheŶ ďouŶd ǁith Cu;IIͿ, 
ǁhiĐh has additioŶallǇ ďeeŶ liŶked ǁith iŶĐƌeased foƌŵatioŶ of oligoŵeƌiĐ aŶd fiďƌous Aβ. 
Cu;IIͿ, as ŵeŶtioŶed pƌeǀiouslǇ, ďiŶds ǁithiŶ the fiƌst ϭϲ ƌesidues of Aβ so this N-teƌŵiŶus 
ĐaŶ ďe used as a ŵodel foƌ  the full-leŶgth peptide. “iŵilaƌ ĐoŵputatioŶal studies haǀe 
shoǁŶ N-teƌŵiŶi of Aβ peptides to ďe effeĐtiǀe ŵodels to ŵake iŶfeƌeŶĐes oŶ iŶteƌaĐtioŶs 
aŶd stƌuĐtuƌes of full-leŶgth Aβϯϰ,ϯϱ. 
IŶ oƌdeƌ to studǇ effeĐts of these ŵutaŶts ǁheŶ ĐooƌdiŶated to Cu;IIͿ, aŶd to Đoŵpaƌe to the 
uŶalteƌed WT, ǁe ƌepoƌt the ƌesults of ŵoleĐulaƌ dǇŶaŵiĐs siŵulatioŶs oŶ Cu;IIͿ-ďouŶd, 
tƌuŶĐated ŵutaŶt aŶd WT peptides Ŷoted iŶ Figuƌe ϭ. This alloǁs us to dƌaǁ ĐoŵpaƌisoŶs oŶ 
seĐoŶdaƌǇ stƌuĐtuƌe aŶd staďilitǇ. Fƌoŵ this, ǁe ĐaŶ saŵple ĐoŶfoƌŵatioŶs aŶd eŶeƌgies of 
eaĐh ŵutaŶt sǇsteŵ, aŶd iŶ doiŶg so ŵake iŶfeƌeŶĐes oŶ aggƌegatioŶ ďehaǀiouƌ Đoŵpaƌed 
agaiŶst liteƌatuƌe. 
 
Computational Methods 
Aβϭ–16 was constructed in an extended conformation in MOE36, with appropriate 
protonation states for physiological pH. Cu was coordinated to the peptides as shown in 
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Figure 2 via Asp1, His6, and His13, i.e. component I37. His14 could have been used in place of 
His13 but we made the decision to choose one of these residues for consistency across all 
simulations. The exception to this was H6R, which was bound via Asp1, His13 and His1438 in 
the absence of His6.  All constructed peptides were subjected to brief LowMode39 
conformational search to obtain starting structures. MD simulations were performed using 
the AMBER1640 package. The AMBER ff14SB41 forcefield parameter set was used to model 
all standard amino acid residues, while parameters for the metal and bound residues were 
obtained using the MCPB.py program42. Here, parameters are obtained from B3LYP/6-
31G(d), and RESP charges for the metal-coordinating regions were obtained at the same 
level of theory using Gaussian0943. Semi-empirical calculations used the GFN2-XTB method44 
ǁithiŶ Gƌiŵŵe’s ǆtď package45. 
 
Figure 2 Coordination mode of Cu(II) to Aβ modelled across all simulations 
 
The geometry of each system was optimised using 1000 steps of steepest descent and 1000 
steps of conjugate gradient methods. MD simulations were carried out in the NVT 
ensemble, using a Langevin thermostat to control the temperature at 310 K. Three separate 
500 ns MD simulations of each Cu-mutant complex were carried out, starting from the same 
minimised structure but with different initial velocities, randomly sampled from the 
Maxwell-Boltzmann distribution at 310 K. Electrostatic interactions were neglected beyond 
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a cut-off of 12 Å, and the Generalised Born solvation model used to solvate all 
systems46,47,48: this approach has been shown to enhance conformational sampling of 
flexible systems. During all simulations, the SHAKE algorithm49 was used to constrain bonds 
to hydrogen. Simulations were performed using a 2 fs integration timestep. Equilibration 
times were taken from RMSD data for all simulations, all pre-equilibrated data from the 
three 500 ns runs were excluded and the rest was combined to form full individual 
tƌajeĐtoƌies to ďe aŶalǇsed foƌ all eight sǇsteŵs. This led to aƌouŶd ϭ.ϰ μs of data ĐolleĐted 
for each peptide. Analysis of the trajectories was performed using CPPTRAJ v16.1650 and 
VMD 1.9.351. Ramachandran maps were made using MDplot52 with nomenclature used to 
describe these from Hollingsworth & Karplus53.  
 
 
Results 
Root mean square displacement (RMSD) of all backbone atoms relative to starting structure 
was used as the primary measure of equilibration. Plots of backbone RMSD for each run 
show that simulations reach stable values after between 5 and 70 ns. All analysis reported is 
taken from data extracted from frames after these equilibration points,54 averaged over 
three separate runs. Once these frames were combined, this led to over 1.4 s of simulation 
data collected and analysed for each system. Run A for D7H took the longest amount of 
time to equilibrate out of all simulations, before reaching a conformational ensemble similar 
to the other two runs. Averages and standard deviations of RMSD collected over frames 
after the selected equilibration point (Table 1) confirm equilibration: averages are in the 
range 2 to 5 Å with standard deviations between 0.3 and 1.2 Å. K16N stands out in this data 
as being particularly immobile, having the smallest maximum, mean and standard deviation 
from the starting point. H6R also has small sd, although maximum and mean values are 
larger than for WT and K16N. Most other mutants exhibit similar properties, A2V is the only 
simulation with a larger sd value than WT, indicating greater flexibility within this mutant.  
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Table 1 Statistical analysis of RMSD data (Å) 
 Avg Min Max SD 
WT 3.84 1.54 6.43 0.80 
A2T 3.92 2.04 6.17 0.53 
A2V 5.09 2.65 7.18 1.23 
H6R 4.57 2.81 6.85 0.29 
D7H 3.11 1.77 4.02 0.40 
D7N 3.87 2.05 6.37 0.70 
E11K 4.08 2.23 5.26 0.52 
K16N 2.39 1.30 3.42 0.28 
 
Table 2 reports post-equilibration radius of gyration (Rg) data, which show that on average 
most mutants are smaller than the wild-type peptide, even in cases where the mutated 
residue is larger than the one it replaces, such as A2V. E11K has an average value similar to 
WT: given the larger size of Lys over Glu, this also indicates a compact set of conformations. 
K16N is particularly small, in accord with low RMSD values noted above, although some of 
this change may stem from the smaller size of Gln compared to Lys. Standard deviations are 
small for all cases, further demonstrating the equilibration of the relevant trajectories. D7N 
exhibits the most variability as well as the largest average size and sd, but amongst mutants 
there is no obvious relationship between Rg and RMSD data. For instance, in the Rg values 
for A2V compared to WT suggesting a decrease in size despite its RMSD data. This suggests 
that the relatively large RMSD value for A2V correspond to motions that do not affect the 
overall size of the peptide. Solvent accessible surface area (SASA) per residue calculated 
over post-equilibration trajectories (Table S4) are almost identical for analogous residues 
between mutants, indicating all residue are fully solvent-exposed. 
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Table 2 Post equilibration Rg data (Å) 
 Avg Min Max SD 
WT 7.90 6.77 9.68 0.44 
A2T 7.62 6.70 9.66 0.44 
A2V 7.37 6.74 8.66 0.24 
H6R 7.26 6.75 8.65 0.20 
D7H 7.29 6.72 8.21 0.23 
D7N 8.14 6.78 9.98 0.49 
E11K 7.90 6.90 9.51 0.32 
K16N 7.04 6.40 8.74 0.23 
 
Root mean square fluctuation (RMSF) of each residue for all trajectories in each system are 
reported and illustrated in Figure 3. Although there is substantial scatter in the data, some 
trends are apparent. The mutated residues themselves do not stand out as having unusual 
properties: residue 11 in E11K is flexible, but values are high for residue 11 in other systems. 
N-terminal residues are typically less mobile than C-terminal ones, with residue 16 being 
particularly flexible in all cases. In agreement with RMSD data, K16N has low RMSF values 
for all residues. Interestingly, H6R values are also rather low, with the exception of residues 
10 & 11 and as mentioned before, residue 16. This agrees with low Rg and RMSD data 
despite H6R having one of the highest average RMSD values. In contrast, numerous residues 
in A2V have high RMSF values, but these are not located at or even near the mutation; 
instead largest values are centred on residues 10-12. Copper-binding residues (1, 6 and 13 
for most systems, 1, 13 and 14 for H6R) are among the least mobile, indicating that the 
ŵetal aĐts as aŶ ͞aŶĐhoƌ͟ to ďouŶd aŵiŶo aĐids. This is espeĐiallǇ Ŷotaďle foƌ HϲR, 
suggesting that metal binding to adjacent residues reduces flexibility more than to those 
that are separated. Bound residues are also notably more rigid in the K16N mutant 
compared to all other simulations.  
It is interesting to note the relative differences in RMSF values between peptides containing 
mutations at similar positions such as A2T/A2V and D7H/D7N. These proteins with relatively 
similar amino acid sequences would be expected to display similar figures, yet there is 
8 
 
contrasting data shown between systems for bound residues such as Asp1 which showed 
variance in RMSF values of 2.33 Å for D7H and 3.33 Å for D7N. As well as this, values differ 
for both the site of mutation as well as throughout the whole peptide structure displayed in 
RMSF data for the mutated residues of A2T & A2V of 1.83 and 2.99 Å respectively. In 
addition, we report a difference of 2.73 Å between values for Val12 and 2.51 Å for Glu11 in 
these two systems. Reduced incidence of salt-bridges at position Glu11 in A2V allow for 
increased mobility of residues around this point as shown from the differing values between 
the two mutant proteins. 
 
Figure 3 RMSF data per residue (Å) 
 
Clustering further highlights the trends in stability/mobility between mutants: Table 4 
reports the number of clusters, and the percentage population of the most and second-
most prevalent ones calculated from the DBSCAN clustering algorithm in CPPTRAJ48.  This 
shows that K16N in particular, but also H6R, fall into a single dominant cluster, reflecting the 
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lack of flexibility and variation in RMSD and Rg discussed above. WT and D7H form a 
relatively highly populated single cluster, albeit with lower prevalence, while A2T, A2V, D7N 
and E11K fall into several clusters with smaller populations. Views of a representative 
snapshot of the most populated cluster for each mutant are shown in Figure 4 indicating the 
change of peptide structure relative to the metal-binding site and site of mutation for all 
simulations. These show i) the consistency of the metal binding site and ii) the variability 
and overall lack of defined secondary structure in any given snapshot. The latter is explored 
in more detail below. 
 
Table 4 Cluster analysis on equilibrated trajectories 
 
 
 
 
 
 
 
 
 
 
 
 
Mutant # Clusters Most populated 
(%) 
Second Most 
Populated (%) 
WT 10 64.1 1.5 
A2T 11 45.9 30.2 
A2V 9 32.6 31.5 
H6R 7 89.9 5.9 
D7H 4 63.8 34.6 
D7N 12 49.3 24.1 
E11K 16 30.3 28.8 
K16N 1 99.8 N/A 
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Figure 4 Highest populated clusters for each simulation. Top row (L-R) WT, A2T, A2V, H6R; Bottom 
Row (L-R) D7H, D7N, E11K, K16N. Cu is represented as the teal ball, relevant atoms on coordinated 
sites as well as mutated residues are shown as wireframe. Protein back bone is characterised by its 
secondary structure: red = α-helix, blue = turn & white = random coil. 
Structural comparisons were made via (Cα) of the backbones of the two most-prevalent 
clusters for all peptides using the UCSF Chimera55 software tool. The most frequently 
occurring cluster for WT and A2T have RMSD = 0.970Å. These two clusters also showed high 
similarity to that of the second most-populated cluster for D7N at 0.374Å and 0.905Å 
respectively: the structures of all 3 are compared in Figure 5. 
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Figure 5- Comparison of Cα on peptide backbones of cluster structures showing highest 
levels of similarity from RMSD data. Tan- WT, Blue- A2T, Purple- D7N, Orange Sphere- Cu 
Salt-bridges play an important role in peptide structure: percentage populations of all 
possible combinations of oppositely charged residues across equilibrated trajectories are 
displayed in Figure 6. Data shows that all mutations have a strong effect on the number and 
distribution of salt bridges. Compared to WT, the two mutations that leave the number of 
charged residues unchanged, A2T and A2V, reduce the frequency of Asp1-Arg5 and increase 
that of Asp7-Lys16 in A2V, while the incidence of Glu11-Arg5 and Glu11-Lys16 is also 
diminished in A2V but remain consistent in A2T. Salt-bridge profiles between these two 
mutants show contrasts in types of interaction and frequency with Glu3-Lys16 and Asp7-
Lys16 present in A2V but absent in A2T, whilst Asp1-Lys16 interactions appear only in A2T. 
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Figure 6- Salt bridge plots by percentage for equilibrated simulations. Top row (L-R); WT, A2T, A2V, 
H6R. Bottom row (L-R); D7H, D7N, E11K, K16N. 
 
H6R introduces an extra positively charged residue, which interacts most commonly with 
Glu3, but also Glu11 and occasionally Asp7. Glu3 is also found in contact with Arg5 for 
almost every recorded frame: the close proximity of these residues is illustrated in Figure 7, 
showing that Glu3 bridges between the two adjacent positive residues. The presence of 
Arg6 also acts to remove completely the interactions of Arg5 with both Asp1 and Glu11, and 
also the Glu11-Lys16 link, that were prevalent in WT.   
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Figure 7- View of H6R, with sidechains of Glu3, Arg5 and Arg6, along with metal binding site, 
shown as wireframe, and the backbone of the remaining peptide as a ribbon 
In contrast, D7N and D7H remove a negatively charged residue: however, Asp7 is not heavily 
involved in salt bridges in WT, such that the pattern of salt bridge population is closest to 
WT for these mutants. Some changes are still evident, such as a reduction in the interactions 
of Asp1, with concomitant increase in contacts to Glu3 in D7H. The two mutations of Asp7 
show a decrease in the occurrence of Glu11-Arg5 and an increase in Glu11-Lys16 salt-
bridges compared to WT but remain consistent with each other at relatively similar levels of 
incidence. 
E11K swaps the sign of residue 11: the introduced positive sidechain does not engage in any 
significant interactions. The loss of Glu11 leads to changes in interactions of Arg5 and Lys16, 
especially with Glu3, and also to the complete loss of interactions of Asp1. K16N removes a 
positive residue, leaving only Arg5, which forms a highly populated bridge to Asp7, but no 
other significantly populated interactions. Across all the simulations, the most commonly 
observed salt bridge is that between Glu11-Lys16, at 46% of all possible frames, while Asp1-
Lys16 is observed for only 3.2% of the full set of equilibrated trajectories. 
Contact maps show average distances (Å) between Cα within the peptide backbone per 
residue (Figure 8). These maps reflect the patterns in flexibility noted above: for instance, 
the least mobile peptides K16N and D7H display large areas of short contact (blue in Figure 
8), whereas the most flexible ones W2T, A2T and D7N exhibit large areas of longer average 
14 
 
contacts (orange/red in Figure 8). However, the precise pattern of contacts varies: short 
contacts between Ala2-His6 and Tyr10-Glu11 are present in K16N, while the closest contacts 
in D7H are between Gln15-Lys16 and His6-Tyr10. High incidences of salt-bridges formed 
such as with Glu3-Arg5 in E11K are also seen as short distances contact maps. 
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Figure 8 Contact map of average distance between Cα (Å). Top row (L-R); WT, A2T, A2V, H6R. Bottom row (L-R); D7H, D7N, E11K, K16N. 
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Ramachandran plots for all post-equilibration frames for all mutants are shown in Figure 9. 
IŶ WT, the highest iŶĐideŶĐe is fouŶd ǁithiŶ the α-region, centred on φ, ψ = -63, -43, 
followed by PII  (-105, 100 to -30, 200) aŶd β ;-180, 90 to -ϭϬϱ, ϭϵϬͿ, as ǁell as soŵe ɷ’ 
character (35, 60 to 100, -ϮϱͿ, at siŵilaƌ leǀels to those fouŶd iŶ the β ƌegion. A2T, A2V, and 
H6R have similar Ramachandran maps, showing increased population of PII and reduced of 
α, whilst maintaining relatively siŵilaƌ leǀels of β ĐhaƌaĐteƌ to WT. DϳH diffeƌs fƌoŵ the 
others, as both the PII aŶd α ƌegioŶs aƌe eƋuallǇ populated, and also as the only plot to 
possess a sigŶifiĐaŶt aŵouŶt of ĐhaƌaĐteƌ ǁithiŶ the ɷ ƌegioŶ ;-30, -65 to -135, 40).  
D7N differs from D7H showing less PII character than its Asp7 counterpart as well as an 
iŶĐƌease iŶ ɷ’ ŵakiŶg it the ŵost Đoŵpaƌaďle plot to WT. E11K has similar level of PII aŶd α, 
ǁith less β ĐhaƌaĐteƌ thaŶ otheƌs ĐoŶsideƌed. This plot also has the most incidence of 
conformations with positive φ, which for non-glycine residues is usually an indicator of 
steric hindrance. K16N is broadly siŵilaƌ to WT, ǁith ŵost ƌesidues loĐated ǁithiŶ the α-
region, but this mutant lacks any PII ĐhaƌaĐteƌ, ǁith gƌeateƌ populatioŶ of the β-region, albeit 
spread out over a broader distribution then seen in the other plots. 
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Figure 9- Ramachandran plots for equilibrated trajectories. Top row (L-R); WT, A2T, A2V, H6R. 
Bottom row (L-R); D7H, D7N, E11K, K16N. Red areas indicate most prevalent character, blue regions 
indicate lower levels of incidence and white is an absence of character. X-axis = φ[o], y-axis = ψ[o]. 
 
The effect of mutations on secondary structure are marked and varied, as shown in Table 5. 
WT is characterised by a large amount of coil (at termini) and turn (residues 3-5 and 8-10), 
along with 3,10 helices and some -strand but almost no α-helix. This is apparently at odds 
with the Ramachandran plot for WT above, which shows high concentration of frames lying 
in the region associated with α-helical structure. It is, however, in accord with Hollingsworth 
aŶd Kaƌplus’s fiŶdiŶg that ƌesidues that aƌe Ŷot Đlassified as heliĐal aƌe still fouŶd iŶ this 
region of -ψ spaĐe, aŶd aƌe peƌhaps ďetteƌ thought of as ďeloŶgiŶg to ͞aŶ eǆteŶded -
ƌegioŶ͟.  
A2T shows the greatest increase in helical character over the whole sequence whilst losing 
soŵe of its β-character, whereas A2V only displays α-helix across residues 3-7 as well as an 
increase in -strand content. H6R exhibits very little helix or strand structure, being 
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dominated by coil/turn/bend structure with only small elements of 3,10-helix and strand 
located mainly between residues 6-10.  
D7H shares similarities to WT, albeit with greater proportions of -strand. D7N and D7H are 
Đlosest iŶ ƌeseŵďlaŶĐe to eaĐh otheƌ iŶ teƌŵs of α-content despite notable variances in salt-
bridge profiles suggesting a difference in structures. In D7H, the presence of helical 
geometry is limited to residues 3-6 whilst D7N displays this between 3-5 but also towards 
the C-termini between residues 13-16. The percentage of strand character differs between 
these two mutant systems ǁith DϳH displaǇiŶg β-characteristics over a larger range of 
residues than D7N.  
E11K displays almost no helix content and predominantly forms coil/turn/bend formations 
making up the predominant character of its secondary structure. K16N leads to strand 
content closer to the N-terminus and helices at the C-terminus at incidence levels 
comparable to that of WT. No clear pattern of changes in the mutated residues themselves 
is found, such that changes to secondary structure are global rather than local. 
Table 5 Percentage of residues classified as helical, strand, or other 
 Helix Strand Other 
WT 14.5 2.4 83.1 
A2T 31.0 0.5 68.5 
A2V 8.9 4.2 86.9 
H6R 3.6 0.3 96.1 
D7H 11.4 7.2 81.4 
D7N 11.6 1.3 87.1 
E11K <0.1% 4.9 95.0 
K16N 13.8 3.9 82.3 
 
Average binding energies of Cu(II) to each peptide were calculated using the semi-empirical 
GFN2-xTB method, and reported in Table 7. Structures were taken every 100 ns from all 8 
equilibrated trajectories of appƌoǆiŵatelǇ ϭ.ϰ μs and minimised, before calculation of the 
total energy of Cu-peptide complex + 4(H2O) compared to the free peptide and 
[Cu(H2O)4]2+, all in implicit model of aqueous solvent. No major conformational changes 
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were observed following optimisation shown by RMSD values comparing structures 
generated in AMBER and minimised structures from xTB. 
Most binding energies are typically in the range of -70 to -110 kJ mol-1, indicating that most 
peptides considered have similar affinities for binding with copper ions. H6R is one of the 
closest in binding energy to WT, despite possessing an extra positively charged residue and 
a different mode of bonding from all other simulations. However, Cu(II) is more strongly 
bound to WT, whereas binding to K16N is markedly weaker than all other systems with 
binding energy of -30 kJ mol-1. All mutant peptides had a lower average difference in binding 
energy compared to the WT showing weaker binding to the metal centre. Relatively high 
standard deviations indicate a wide range of values for binding energies for all mutant 
simulations indicating a high level of variability across trajectories. Average binding energies 
are displayed with standard deviations in Figure 10. 
 
Figure 10- Binding energies with standard deviations for each mutant 
 
Discussion 
MD simulations of Cu-complexes of N-terminal mutants yielded evidence that the effects of 
poiŶt ŵutatioŶs of Aβ ǀaƌy significantly and depend on the site of mutation as well as the 
specific amino acids involved. We find marked differences between mutants in secondary 
structure, conformations adopted, and flexibility/stability.  
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Within the mutations that do not alter charge state, i.e. A2V and A2T, greater flexibility was 
observed in A2V compared to WT, despite it adopting more compact conformations, as 
shown by Rg data. In conjunction with RMSF results, we observed that the greatest 
contribution to this more mobile nature occurs after Tyr10 peptide, but increased 
movement was noted across entire structure. A2T however, displayed less flexibility than 
both A2V and WT in addition to adopting conformations comparable in size to WT shown via 
similar Rg values. Additionally, A2T showed less mobility in its RMSF values after Tyr10 in 
direct contrast to A2V due to a notable decrease in formation of salt-bridges with Glu11 in 
the latter. Trajectories for these mutants fall into a similar number of clusters as the WT, 
albeit with more evenly distributed population, further confirming their dynamic nature. As 
charge is unchanged and sequences relatively similar, we expected to see similar salt-bridge 
profiles. Instead, the incidence and combinations of these attractive forces displayed 
notable differences from the WT protein and each other, with only Glu11 interactions 
remaining consistent between WT and A2T. Several salt-bridges formed in the A2T and A2V 
simulations were rather transient, further demonstrating the constant fluctuation of atoms 
and residues in these systems over the course of the simulations.  
H6R and K16N are similar in terms of structure and stability. RMSD and Rg data show they 
adopt more rigid and compact conformations compared to WT, with lower RMSF values per 
residue, demonstrating the stability of these mutated peptides. Further evidence of this is 
exhibited in cluster analysis: both adopt a single prevalent structure over the course of their 
simulations. Addition of a positive residue in H6R peptide was expected to yield an increase 
in salt-bridge formation at Arg6, which was indeed found. However, some salt-bridges 
present in WT are lost completely while new ones are observed remotely from the site of 
mutation. In contrast, K16N loses a positive residue and thus has reduced potential for salt-
bridges, evident in the fact that only one such interaction forms for an appreciable time, 
suggesting that the stability of this mutant cannot be accounted for by these forces. The 
Ramachandran plot lacks PII character, present in all other simulations, but shows increased 
presence of organised α aŶd β-character, which may be the origin of the relative stability.  
D7H and D7N mutants have contrasting properties, unanticipated for two different 
mutations at the same site, including RMSD and Rg compared to WT, indicating they possess 
different structures. D7N being more comparable to WT than D7H which is much lower for 
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both RMSD and Rg indicating it possesses a more rigid, compact set of conformations. RMSF 
data clearly shows the differences between these peptides: values for residues in D7N are 
consistently higher than WT across the whole peptide, whereas D7H has values generally 
similar to or much lower than WT especially in residues towards the C-terminus. This is also 
evident in clustering data, which indicate D7H populates fewer conformations than D7N, 
which is more comparable to the A2T/A2V systems, occupying a greater number of more 
sparsely populated clusters. These differences between systems are also seen in 
Ramachandran plots: D7H has an even distribution between PII aŶd α ƌegioŶs, as ǁell as 
sigŶifiĐaŶt ɶ-character, whereas D7N has a Ramachandran plot comparable to WT with 
similar population of PII, α, aŶd eǀeŶ ɷ’ consistent with the unmutated peptide. Mutation of 
Asp7 was not expected to strongly affect salt-bridges, as this residue is barely involved in 
these interactions in WT. However, this was not the case with significant differences in 
nature and incidence of interactions. Glu-11 interactions were consistent with one another 
but at different levels to WT, additionally no other salt-bridges formed at significant levels in 
these two mutant systems. 
E11K adopts a less rigid conformation than the other peptides simulated. Average Rg for this 
system is the same as WT, but the increased size of Lys means that E11K adopts a more 
compact structure than the WT overall. Despite this, RMSF data is greater for all residues in 
E11K compared to WT, indicating greater flexibility. Additionally, this mutant forms the 
highest number of clusters. This particular variant substitutes a positive residue for a 
negative one, but the new Lys forms no significant salt-bridge interactions, and also 
eliminates all salt-bridges of Asp1 that were present in WT. The Ramachandran plot for this 
stƌuĐtuƌe displaǇs a sigŶifiĐaŶt populatioŶ iŶ the positiǀe φ side, usuallǇ iŶdiĐatiǀe of steƌiĐ 
hindrance, which could be the origin of the flexibility of this mutant. 
Overall, a decrease in helical character was observed in all simulations compared to WT 
except A2T: some mutants lose nearly all helical structure, such as E11K, whereas formation 
of helices increased in A2T by more than double. IŶĐƌeased β-character was recorded in 
most simulations, with the exceptions of A2T, H6R, and D7N which saw a decrease or similar 
levels of β-strand structures compared to WT. Previous studies have shown a link between 
β-character and enhanced aggregational properties56. The laĐk of β-strands in simulation 
data for A2T, provides supporting evidence for the protective nature of this mutant57. H6R, 
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D7H, and D7N have been shown in similar MD simulations58 to foƌŵ aŶ iŶĐƌeased leǀel of β-
character which held true for the D7H simulation data we report. It can be expected that the 
monomeric forms of mutant species reported here may not generate results indicative of 
those observed in oligomeric species associated with enhanced neurotoxicity and 
aggregation59 however the results we have generated for the truncated species seem to be 
in agreement with siŵilaƌ MD eǆpeƌiŵeŶts oŶ laƌgeƌ Aβ peptides. 
D7H and D7N were most comparable to one another, despite their contrasting results in 
other analyses, whereas K16N was most similar to the unaltered WT peptide. We find that 
the effects of mutations on peptide structure is global as opposed to local, as evident in 
from the varied salt-bridge profiles for each mutant, which exhibit changes in interactions 
and structures remote to the site of mutation in all analysis. Ramachandran plots and 
secondary structure analysis show distinct differences and similarities between systems and 
highlight the contrasts in structure between comparable mutations at a similar location such 
as A2T/A2V and D7H/D7N.  
 
Conclusions 
In this study, we used MD simulations to explore the effects of N-terminus genetic 
ŵutatioŶs oŶ the tƌuŶĐated Aβ 1-16 peptide when bound with Cu(II), with the aim of finding 
differences between mutants and drawing comparisons of these variants with the WT 
peptide. Literature data indicates varying effects on pathogenicity and structure between 
mutants. All mutants varied in terms of rigidity and size, as seen in RMSD and Rg data 
comparable to WT as well as one another, showing these mutations have differing effects 
oŶ ŵoƌphologǇ of the Aβ peptide. We oďseƌǀed ĐoŶfoƌŵatioŶal ĐhaŶges ďetǁeeŶ eaĐh 
system from this data in conjunction with cluster analysis showing varying degrees of 
mobility. 
Results for different mutations at similar locations were independent of each other, showing 
some similarities as well as distinctions between systems such as D7H compared to D7N. 
From this it can be ascertained that both the location and type of mutation that alters the 
structure of the peptide. Salt-bridge data was markedly varied between simulations and in 
conjunction with Ramachandran plots showing different profiles for each mutant, showed 
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that the changes are not local to the site of mutation, and that overall structure should be 
considered when comparing such systems. 
In nearly all cases, the levels of helical character decreased in comparison to WT, forming 
eitheƌ ŵoƌe β-character or coil/turn/bend. Previous studies have shown an incƌease iŶ β-
sheets have been the driving force for aggregation. It is interesting to note that the decrease 
iŶ β-character observed in A2T is in agreement with the previously reported protective 
nature of this mutation19. E11K and A2V display an increase in β-strand like structures which 
was expected due to their reported pathogenicity16,17. Despite our simulations only being 
performed on the truncated, monomeric peptides, the MD results reported indicate that 
these are effective models of the full-leŶgth Aβ and inferences of the effects of these 
genetic mutations can still be made from this data. We hope to report analogous data for C-
terminal mutants on the full peptide in due course. The impact of mutations on aggregation 
properties could be explored further by using MD to further model peptides dimers or 
oligomers in systems that closer replicate those in vivo. 
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Plots of RMSD and Rg over time, equilibration times, numerical salt bridge data is available 
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